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In vivo 13C NMR spectroscopy has the unique capability to measure metabolic fluxes noninvasively in the brain. Quantitative
measurements of metabolic fluxes require analysis of the 13C labeling time courses obtained experimentally with a metabolic model. The
present work reviews the ingredients necessary for a dynamic metabolic modeling study, with particular emphasis on practical issues.
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Carbon-13 NMR spectroscopy is a powerful tool to
investigate intermediary metabolism. The high chemical
specificity of 13C NMR, which can distinguish 13C isotope
incorporation not only into different molecules, but also
into specific carbon positions within the same molecule
(13C isotopomers), allows one to follow the fate of 13C label
through multiple metabolic pathways. However, the inter-
pretation of 13C NMR data to derive quantitative metabolic
fluxes requires analysis with a metabolic model. This
metabolic modeling is particularly complex in the brain
due to the highly organized interaction between different cell
types corresponding to different metabolic compartments.
The potential of 13C NMR spectroscopy to study
metabolic pathways was demonstrated using suspensions
of microorganisms [1,2]. The first attempt to model the flow
of 13C label into the TCA cycle was made in 1983 by
Chance et al. [3] in the heart, at a time when such analysis
required some of the fastest computers available. Initial
studies in the brain in vivo were reported in the late 1980s
and early 1990s [4–7]. Since then, the steady increase in
magnetic fields available for in vivo studies and progress in
NMR methodology have allowed detection of 13C labeling
time courses in localized regions of the brain with
constantly improving sensitivity. In parallel, methods for0730-725X/$ – see front matter D 2006 Elsevier Inc. All rights reserved.
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models into complex two-compartment models. Together,
these improvements have allowed 13C metabolic modeling
studies to make important contributions to our understand-
ing of brain metabolism and compartmentation, showing for
example that the glutamate–glutamine cycle is a major me-
tabolic pathway in the brain [8,9], that the neuronal TCA
cycle rate increases with neuronal activity [10–12], that glial
TCA cycle is significant in the brain [13] and that anaplerotic
pyruvate carboxylase activity is significant in the brain [13]
and increases with neuronal activity [14].
The aim of this review is to provide the reader with an
overview of the experimental design for a 13C metabolic
modeling study. This is not intended as a comprehensive
review of the field of 13C metabolic modeling, but rather as a
practical guide for readers (not only NMR spectroscopists,
but also neuroscientists in general) interested in understand-
ing the experimental details of such studies. The emphasis
has been placed on metabolic modeling rather than NMR
spectroscopy, and NMR spectroscopy methodology is
described only when it is relevant to metabolic modeling.
We refer the reader to recent reviews for further details on
NMR methodology [15,16].
We have chosen to focus in this review on metabolic
modeling which uses a one-compartment model and
[1-13C]glucose or [1,6-13C2]glucose as a metabolic substrate.
Other tracers and more complex metabolic models can be
used, such as two-compartment (neuron–astrocyte) models.aging 24 (2006) 527–539
Fig. 1. Overview of a 13C metabolic modeling study.
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and is well suited for explaining the principles of metabolic
modeling. We have also chosen to focus on bdynamicQ
metabolic modeling, meaning modeling of 13C labeling
time courses. Therefore other analysis methods such as iso-
topomer analysis will not be considered in this review.
13C metabolic studies commonly involve four steps
(Fig. 1):
(1) choice of 13C-labeled substrate and infusion protocol
(2) detection of 13C label incorporation into brain
metabolites during infusion of 13C labeled substrate
(3) quantitation of 13C spectra to obtain 13C turn-
over curves(4) metabolic modeling of 13C turnover curves to
obtain quantitative fluxes through specific biochem-
ical pathways
In the following sections, each of these steps will be
examined separately, with a focus on the relevance of each
aspect to metabolic modeling.2. Choice of 13C-labeled substrate and infusion protocol
2.1. Choice of 13C-labeled substrate
The first step in the design of a 13C metabolic study is the
choice of a metabolic substrate. Since glucose is the main
Fig. 2. 13C flow from [1-13C]glucose into brain metabolites. (A) 13C label flowing through pyruvate dehydrogenase labels the C4 of glutamate in the first turn
of the TCA cycle and the C3 and C2 of glutamate in the second turn. (B) 13C label flowing through pyruvate carboxylase labels the C2 of glutamate, but not the
C3, leading to differential labeling of C2 and C3 positions of glutamate. See text for details.
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substrate for metabolic studies in the brain. Most in vivo
metabolic studies have been performed using [1-13C]glu-
cose or [1,6-13C2]glucose. Both substrates lead to the
formation of [3-13C]pyruvate, with [1-13C]glucose generat-
ing one unlabeled pyruvate and one labeled pyruvate per
molecule of glucose, while [1,6-13C2]glucose generates
two molecules of [3-13C]pyruvate per molecule of glucose.Knowledge of metabolic pathways through which the
infused 13C-labeled substrate can be metabolized is, of
course, essential for the interpretation of 13C NMR data.
The flow of 13C label from [1-13C]glucose or [1,6-13C2]glu-
cose into brain amino acids is shown in Fig. 2. Note that
this figure does not take into account cellular compartmen-
tation. For example, the enzyme pyruvate carboxylase is
localized exclusively in astrocytes. See Section 4.6 for further
P.-G. Henry et al. / Magnetic Resonance Imaging 24 (2006) 527–539530discussion of metabolic modeling using two-compartment
models.
Through glycolysis, [1-13C]glucose (or [1,6-13C2]glu-
cose) generates [3-13C]pyruvate. Pyruvate can then be meta-
bolized either through pyruvate dehydrogenase (Fig. 2A) or
pyruvate carboxylase (Fig. 2B).
Through pyruvate dehydrogenase (Fig. 2A), [3-13C]py-
ruvate yields [2-13C]acetyl-CoA, which then combines with
an unlabeled molecule of oxaloacetate to generate citrate
labeled at the C4 position. Subsequently, a-ketoglutarate
(also called 2-oxoglutarate) becomes labeled at the C4
position. The large pool of cytosolic glutamate then becomes
labeled at the C4 position through transamination of
[4-13C]a-ketoglutarate and transport through the mitochon-
drial membrane. 13C-label then goes on to label glutamine
and GABA. At the same time, 13C label continues to flow
into the TCA cycle, labeling succinate. Since succinate is a
symmetric molecule, the C2 and C3 positions of succinate
cannot be distinguished and become labeled with equal
probability. The first turn of the TCA cycle is completed
when oxaloacetate becomes labeled at the C2 and C3
positions, eventually leading to labeling of aspartate at the
C2 and C3 positions. Labeled molecules of oxaloacetate can
combine again with labeled (or unlabeled) acetyl-CoA and
will label the C2 and C3 positions of glutamate in the second
turn of the TCA cycle.
The alternate pathway through pyruvate carboxylase
(Fig. 2B) generates [3-13C]oxaloacetate from [3-13C]pyru-
vate. [3-13C]Oxaloacetate then yields [2-13C]citrate,
[2-13C]a-ketoglutarate and [2-13C]glutamate. Since the
pyruvate carboxylase pathway labels glutamate C2, but
not glutamate C3, it introduces differential labeling of
glutamate at the C3 and C2 positions.
Most of the molecules that become labeled during a
[1-13C]glucose infusion cannot be detected by NMR in vivo
due to their low concentration and the relatively low sen-
sitivity of in vivo NMR. Only the more concentrated amino
acids glutamate, glutamine, aspartate and (if sensitivity is
sufficient) GABA can be detected. These amino acids are
not part of the TCA cycle, but reflect TCA cycle activity
because they get labeled from TCA cycle intermediates a-
ketoglutarate and oxaloacetate.
Although most in vivo 13C metabolic modeling studies
have used [1-13C]glucose or [1,6-13C2]glucose infusions,
other substrates have been used, e.g., [2-13C]glucose [17],
[1,2-13C2]acetate or [2-
13C]acetate [18,19], or [2,4]
h-hydroxybutyrate [20]. Modeling with nonglucose sub-
strates is complicated by the fact that, in contrast to glucose,
the rate of uptake of 13C-label into brain metabolism is
dependent on the substrate concentration in the blood.
2.2. Infusion protocol
The infusion protocol determines the time courses of
concentration and isotopic enrichment in the blood. For in
vivo studies, the infusion protocol is usually designed toreach a high isotopic enrichment in order to attain sufficient
sensitivity for NMR detection.
Knowledge of the time course of substrate concentration
and isotopic enrichment, or b input function Q, is critical for
deriving quantitative information from 13C labeling time
courses. Without knowledge of the input function, the rate
of labeling of, e.g., glutamate, cannot be interpreted since
one does not know how quickly the 13C-labeled substrate
entered the system. This input function depends on the
protocol used to administer the substrate and on how
quickly the substrate is metabolized. Therefore the infusion
protocol must be adapted for the specific metabolic
conditions under investigation.
An example of infusion protocol often used for metabolic
studies is the hyperglycemic clamp. In this protocol, plasma
glucose concentration is rapidly raised from euglycemic
levels to hyperglycemic levels using a bolus of 99%-
enriched [1-13C]glucose. This bolus mixes with the endog-
enous 12C-glucose in the blood and typically yields about
70% enrichment in plasma glucose within a few minutes.
The bolus is followed by a continuous infusion of 70%-
enriched [1-13C]glucose to keep glucose concentration stable
at two to three times the euglycemia levels. This protocol
results in an input function that is close to a step function,
reaching 70% enrichment within a few minutes and re-
maining at 70% isotopic enrichment thereafter.
However, the time course of plasma glucose isotopic
enrichment does not need to be a step function as long as it
is measured experimentally. For example, glucose can be
administered orally [21,22] and the input function can be
measured using blood samples taken from the subject
throughout the experiment and analyzed for glucose concen-
tration and isotopic enrichment. Alternatively, when blood
cannot be drawn easily inside the magnet, as is the case for
small animals (e.g., mice) with a small blood volume,
additional measurements can be performed on the bench
using the same infusion protocol as in vivo to determine
the input function.
The use of glucose as a substrate presents a number of
advantages for metabolic modeling in the brain. First, it is
generally accepted that brain metabolism is not affected by
glucose concentrations [23], as long as those remain above
a certain threshold. Second, under hyperglycemic condi-
tions, the liver releases little glucose into the blood,
preventing additional sources of labeled substrates to enter
the brain through the circulation.3. Detection and quantification of 13C label. What can be
measured from NMR spectra in vivo?
The next step in the design of a 13C metabolic study is
the detection of 13C label incorporation into brain metab-
olites during infusion of the 13C-labeled substrates and the
quantification of the resulting NMR spectra. Since most
TCA cycle intermediates are not concentrated enough to be
Fig. 3. In vivo localized experimental spectra obtained after 13C-labeled glucose infusion in the rat brain at 9.4 T (top row) and in the human brain at 4 T
(bottom row) using direct detection (left column) and indirect detection (right column). Direct detection spectra were obtained using polarization transfer
[24,25] and indirect detection spectra were obtained using 13C-LASER [26]. Direct detection allowed resolved detection of C4, C3, C2 resonances of glutamate
and glutamine and C3, C2 carbon positions of aspartate. Indirect detection gave better sensitivity (the volume of interest was smaller), but spectral overlap
prevented resolved detection of each individual carbon position. Note the high NAA C6 peak in the human 13C-LASER spectrum (bottom right) due to the fact
that this spectrum was acquired after a very long infusion time.
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label in the larger pools of brain amino acids such as
glutamate, glutamine, aspartate and (if sensitivity is suffi-
cient) GABA.
A fundamental choice in the design of in vivo 13C
experiments is the choice of a method for detection of 13C
label. Detection methods can be broadly classified into
two groups: direct detection at 13C frequency and indirect
detection at 1H frequency. The choice of detection method is
important because it determines what experimental data will
be obtainable for metabolic modeling, which places
constraints on how complex a metabolic model can be used.
The choice of the detection method is closely related
to the choice of the model used for metabolic modeling.
This is because the choice of the detection method deter-
mines what experimental data can be obtained from NMR
spectra, such as which carbon positions can be measured
in which amino acid. What can be measured in vivo is
limited both by the signal-to-noise of NMR spectra and by
the spectral resolution. The signal-to-noise limits detection
to those compounds that have relatively high concentration
and reach a high isotopic enrichment during the 13C
infusion. Spectral overlap, especially with indirect detection,
may prevent quantification of individual resonances corre-
sponding to distinct carbon positions.
In vivo 13C NMR spectroscopy is technically challeng-
ing. Excellent reviews of the technical challenges for both
direct and indirect detection have recently been published
[15,16] and we only summarize them here. The main
limitation of the technique is undoubtedly its low sensitivity,and optimizing sensitivity in turn places strong demands on
RF coil design and pulse sequence development. In
particular, the application of decoupling during acquisition
to improve signal-to-noise and reduce spectral overlap
places constraints on the experimental design to minimize
power deposition (especially in humans) and minimize RF
interference between 1H and 13C channels. Other aspects of
NMR methodology include localization and reduction of
chemical-shift displacement errors.
Time courses of 13C label incorporation can also be
obtained in animals from brain extracts, with the disadvan-
tage that each time point results from several different
animals (cross-sectional measurement) and that measure-
ments may be affected by postmortem changes and
extraction procedures. However, such extracts studies have
allowed studies of brain metabolism in the conscious rat,
whereas in vivo studies require anesthesia to minimize
stress and movement in the magnet. The main advantage of
in vivo detection is to permit measurements of entire 13C
labeling time courses in a single animal, reducing the number
of animals and reducing noise caused by inter-animal
variability. In vivo detection, of course, also makes it
possible to perform noninvasive measurements in humans.
3.1. Direct detection vs. indirect detection of 13C label
Examples of recent spectra obtained with direct and
indirect detection during an infusion of 13C-labeled glucose
are shown in Fig. 3. These show incorporation of 13C label
mostly into amino acids glutamate and glutamine, and with
lower sensitivity aspartate and GABA. Smaller signals from
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illustrate the quandary that the scientist faces when choosing
a detection method. The relative advantages and disadvan-
tages of each method are discussed below.
3.2. Direct detection
The first studies using direct detection in the brain
in vivo were performed by Behar et al. [5] in animals and
by Beckmann et al. [27] and Gruetter et al. [7,24,28]
in humans.
The main advantage of direct 13C detection lies in the very
high chemical specificity of 13C spectroscopy due to the
broad chemical shift range (~200 ppm). This has allowed
resolved and simultaneous detection of C4, C3 and C2
resonances of glutamate and glutamine in both humans [29]
and animals [25]. This, in turn, allows additional data to be
used in the metabolic modeling, making the fitting procedure
more reliable.
Another advantage of direct 13C detection lies in the
additional information from isotopomers. Molecules labeled
at several carbon positions simultaneously appear in 13C
spectra as multiplets, whereas molecules labeled at only one
carbon position appear as singlets. Recent progress in
NMR spectroscopy has allowed detection of these iso-
topomers and quantification of these isotopomers in vivo
[30]. This information can be used to calculate the isotopic
enrichment at different carbon positions. For example, the
doublet of glutamate at the C4 position corresponds to
[3,4-13C2]glutamate and directly reflects enrichment of
glutamate at the C3 position.
In spite of these advantages (high chemical specificity
and additional information from multiplets corresponding
to different isotopomers), direct detection suffers from its
relatively low sensitivity, due to the low gyromagnetic ratio
of 13C. Sensitivity has been improved by the use of higher
field magnets and methodological improvements in NMR
spectroscopy such as RF coils, shimming and new pulse
sequence developments (see Ref. [15] for more details).
3.3. Indirect detection
In contrast to direct 13C detection, indirect 1H[13C]
detection (i.e., detection of 13C label through the attached
protons) offers better sensitivity due to the fourfold higher
gyromagnetic ratio of 1H compared to 13C. The first studies
using indirect detection of 13C label in the brain in vivo
were performed by Rothman et al. [4,31].
This gain in sensitivity is offset by a loss in chemical
specificity due to the smaller chemical shift range of 1H.
This spectral overlap reduces the number of carbon positions
that can be measured using indirect detection and reduces
the amount of experimental data available for meta-
bolic modeling.
Since spectral overlap decreases at higher magnetic field,
more information can be gained at higher field. For
example, separate detection of glutamate C4 and glutamine
C4 (or more precisely detection of signals from protonsattached to glutamate C4 and glutamine C4) has not been
possible so far in 1H[13C] spectra in humans even at 4 T due
to spectral overlap between these two resonances. Due to
the fact that the glutamine 13C labeling time course is
needed to exploit two-compartment models, the inability to
resolve glutamate and glutamine has so far prevented
measurement of glutamate–glutamine cycling in humans
using indirect detection. In humans at 3 or 4 T, most indirect
detection studies have measured glutamate C4 only
[11,31,32], but not glutamine (neglecting contamination of
the glutamate signal by glutamine). The use of higher
magnetic fields (7 or 9.4 T in humans) or the use of new
pulse sequences such as semiselective Proton-Observed
Carbon-Edited may allow separate detection of glutamate
C4 and glutamine C4 in humans in the future [33].
In studies in small animals (e.g., rat brain at 9.4 T), for
which higher magnetic fields are available, glutamate C4 and
glutamine C4 still show some overlap, but the two
resonances can be measured relatively easily using spectral
fitting routines. This is facilitated by the fact that the ratio
glutamine/glutamate is higher in rats than in humans.
However, separate quantitation of glutamate C3 and glu-
tamine C3 remains difficult, due to spectral overlap be-
tween three resonances around 2.1 ppm: GluC3, GlnC3 and
NAAC6. The NAAC6 resonance gets labeled more slowly
than GluC3 and GlnC3. If the 13C infusion time remains
short, NAAC6 can be eliminated by subtracting a natural
abundance spectrum acquired before the beginning of the 13C
infusion, and subsequent labeling of NAAC6 is neglected.
Separate quantitation of glutamate C3 and glutamine C3
has been shown to be feasible at 9.4 T using LCModel
[34,35]. However, a high cross-correlation between GluC3
and GlnC3 remains inevitable, and the use of GlxC3 (i.e.,
GluC3+GlnC3) as a single time course in the modeling
analysis is preferable.
A complication for indirect detection, as pointed out in
recent reports, is the potential bias in NMR quantitation
introduced by strong coupling [36,37]. When strong
coupling is present, the signal at a specific proton chemical
shift may not directly reflect isotopic enrichment of the
attached carbon.
To summarize, direct detection currently allows detec-
tion of time courses for many carbon positions (C4, C3,
C2 of glutamate and glutamine, and C3, C2 of aspartate).
Indirect detection currently provides more limited biochem-
ical information (GluC4 and GluC3 in humans at 4 T,
or GluC4, GlnC4 and GlxC3 in animals at 9.4 T) with
higher sensitivity.4. Metabolic modeling
The fourth and final step in a 13C metabolic study is the
analysis of 13C labeling time courses with a metabolic
model to derive quantitative metabolic fluxes. Time courses
of 13C labeling obtained after measurement and quantitation
Fig. 4. Single pool model. [S] and [P] denote the total concentration of substrate and product, respectively. [S*] and [P*] denote the concentration of labeled
substrate and labeled product, respectively. [S*]/[S] and [P*]/[P] are the isotopic enrichment of substrate and product, respectively. Labeling curves of product
are shown following a step-function increase in substrate isotopic enrichment from natural abundance to 50% at t =0. The isotopic enrichment of the product
increases exponentially to reach the isotopic enrichment of the substrate (isotopic steady-state). The rate of labeling of the product depends not only on the
influx of substrate but also on the size of the product pool.
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tion unless they are further analyzed using a metabolic
model. For example, the rate of labeling of glutamate C4
depends not only on the TCA cycle rate (VTCA), but also on
the exchange rate between a-ketoglutarate and glutamate
(VX) and on total glutamate concentration. Therefore a
change in glutamate labeling time course does not neces-
sarily reflect a change in VTCA.
Metabolic modeling of dynamic 13C labeling time
courses allows for quantitative determination of metabolic
fluxes through specific metabolic pathways. The field of
metabolic modeling is still evolving, with metabolic models
being refined as further experimental data become available.
4.1. Choice of a metabolic model
The choice of the model is guided by the following
questions:
– what are the known biochemical pathways for the
13C-labeled substrate?
– what experimental kinetic data are available from
NMR spectra?
– what metabolic fluxes will be kept as free parameters,
and what biochemical pathways will be assumed
based on previous studies?
The main concern when addressing these questions is to
choose a model that is both accurate (i.e., accurately reflects
the flow of 13C label from substrate to the measured
products) and stable (i.e., does not have too many free
parameters compared to the available experimental data).
Therefore, the more experimental data available for use inthe model, the more complex the metabolic model used to
analyze these data can be.
4.1.1. Single-pool model
The simplest model that can be used is the single-pool
model depicted in Fig. 4. Although simple, this model is
useful to demonstrate a few key points. Two types of
equations can be written for the product pool. The first one
is the mass balance equation, expressing that the variation of
product concentration over time is equal to what enters the
pool minus what exits the pool:
d P½ 
dt
¼ V1  V2
When assuming metabolic steady state, then:
d P½ 
dt
¼ 0 ZV1 ¼ V2
The second equation is the isotope balance equation:
d P*½ 
dt
¼ S*½ 
S½  V1 
P*½ 
P½  V2
If [S],[S*],[P],[P*] are all constant, then this equation can
be solved analytically to yield:
½P* ¼ ½P ½S*½S 1e
V1½P t

If the isotopic enrichment of the substrate [S*]/[S] is a
step function, increasing from 1.1% to 50% at t=0 and
remaining at 50% thereafter, then [P*] increases exponen-
tially to reach a steady-state enrichment of 50% identical to
Fig. 5. One-compartment model describing the flux from [1-13C]glucose into glutamate. (A) Model used to analyze the glutamate C4 labeling curve after
one turn of TCA cycle. (B) Model used to analyze both glutamate C4 and glutamate C3 labeling curves after two turns of TCA cycle.
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of the product is dependent not only on the influx V1 but
also on the concentration of the product [P].4.1.2. One-compartment model of brain metabolism
In most cases, the single-pool model is not sufficient to
accurately measure fluxes such as VTCA in the brain because
the overall flux from, e.g., glucose to glutamate, comprises
several different metabolic fluxes such as VTCA and VX.
One model that has been often used to analyze 13C turnover
curves in the brain is the so-called one-compartment model.
This model describes the flow of [1-13C]glucose either into
glutamate C4 alone (Fig. 5A) or into glutamate C4 and
glutamate C3 (Fig. 5B). Since most glutamate is located in
neurons, fluxes obtained using this model reflect primarily
neuronal metabolism.
An important consideration when choosing the metabolic
model is to decide how many degrees of freedom will beleft (i.e., how many free parameters will be allowed in the
fit, the other parameters being fixed based on assumptions).
For the one-compartment model, up to three free parameters
are typically used: the TCA cycle rate VTCA, the exchange
rate between a-ketoglutarate and glutamate (VX), and the
isotopic dilution rate (VDIL) due to exchange of labeled
lactate with unlabeled lactate. The flux from glutamate to
glutamine (VGLN) is often assumed based on literature
values if glutamine time courses are not measured. As
shall be seen later in this section, the robustness of the fit
can be greatly reduced if too many degrees of freedom are
allowed together with too little experimental data.
The following underlying assumptions have to be
verified for the model to be valid:
– Fluxes are constant over the duration of the exper-
iment.
– Pool sizes are constant (This is often the case, but this
is not an absolute requirement. For example, brain
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beginning of the glucose infusion when going from
euglycemia to hyperglycemia).
– Pool sizes are known.
– Small metabolic pools can be grouped to form a
single metabolic pool (e.g., the oxaloacetate pool
actually represents all pools from succinate to
oxaloacetate).
4.2. Mathematical expression of the model
Once the model has been defined, it is expressed
mathematically in a form suitable for numerical calcula-
tions. Several programs are currently in use for metabolic
modeling. Some have used direct implementation of
differential equations in Matlab [38]. Other programs
feature a graphic interface that allows the user to define
the model graphically (e.g., SAAM, CWAVE). The program
then automatically generates the equations for the numerical
calculations. These programs are very convenient to use, but
may sometimes be less flexible than Matlab, e.g., to perform
Monte Carlo simulations.
Considering the one-compartment model in Fig. 5A,
four differential equations are needed to express the model
in a mathematical form, one for each pool in the model:
pyruvate/lactate (considered as a single pool), a-ketogluta-
rate, glutamate, glutamine. These equations are obtained by
writing the isotope balance equation for each pool. Mass
balance equations are not needed if pool sizes are assumed
to be constant. This gives a set of four differential equations.
For example, the isotope balance equation for lactate is:
d L3½ 
dt
¼ VGLY: GLC1½ 
GLC½   VTCA þ VDILð Þ4
L3½ 
L½ 
This equation expresses that the variation of labeled
lactate over time is equal to the amount of 13C label that
enters the pool coming from glucose VGLY:
GLC1½ 
GLC½ 

minus
the amount of 13C label that exits the pool to the TCA cycle
VTCA
L3½ 
L½ 

and through exchange with unlabeled lactate
VDIL
L3½ 
L½ 

. In this equation, [L3] is the concentration of
lactate labeled at the C3 position and [L] is the total (and
constant) concentration of lactate. Similarly, [GLC1] is the
concentration of brain glucose labeled at the C1 position and
[GLC] is the total brain glucose concentration (not constant
in general). VGLY is the rate of glycolysis and is assumed to
be half of VTCA because one molecule of glucose generates
two molecules of pyruvate through glycolysis.
Similar equations are obtained for the three other
metabolic pools:
d aKG4½ 
dt
¼ VTCA: L3½ 
L
þ VX: GLU4½ 
GLU½   VTCA þ VXð Þ
 aKG4½ 
aKG½ d GLU4½ 
dt
¼ VX: aKG4½ aKG½   VX þ VGLNð Þ
: GLU4½ 
GLU½ 
þ VGLN: GLN4½ 
GLN½ 
d GLN4½ 
dt
¼ VGLN: GLU4½ 
GLU½  
GLN4½ 
GLN½ 

Finally, the time course of brain glucose enrichment
([GLC1]/[GLC]) can be obtained from the time course of
plasma glucose concentration and isotopic enrichment by
adding two more equations for glucose transport (one for
mass balance and one for isotope balance) as in Ref. [13].
Note that the equation for mass balance is needed for
glucose because brain glucose concentration does not stay
constant when going from euglycemia to hyperglycemia at
the beginning of the 13C-glucose infusion.
4.3. Fitting procedure
The system of differential equations describing the model
is in general difficult to solve analytically, but it can be
solved numerically. An overview of the fitting procedure is
presented in Fig. 6.
In order to fit the glutamate C4 labeling time course with
the one-compartment model of Fig. 5A, for example, one
starts with initial values of the free parameters VX and VTCA.
Solving the system of differential equations gives the 13C
labeling time course of glutamate C4 corresponding to the
initial values of VTCA and VX. This time course is compared
with the experimentally measured GluC4 time course by
calculating the fit residuals. Residuals are then minimized
using a least-squares procedure such as Levenberg–
Marquardt to determine the value of parameters VTCA and
VX that give the best fit of the calculated
13C labeling curve
to the experimental data.
A well-recognized potential problem when performing
least-square fitting is the possibility of finding a local
minimum that is different from the absolute minimum. Such
a nonrobust fit is more likely to happen if the problem is
underdetermined (too many free parameters compared to
available experimental data).
Inspection of the fit residuals indicates whether there is
any systematic bias in the fit. Nonrandom residuals can
point to an inaccurate model, an inaccurate input function or
inaccurate quantitation of NMR data. In all cases, nonran-
dom residuals should alert the scientist about potential flaws
in the analysis.
4.4. Evaluation of fit reliability: Monte Carlo simulations
Given the complexity of metabolic models, it is essential
to make sure that the analysis is robust and that the fit is not
unstable, a situation that happens typically when there are
too many degrees of freedom in the model compared to the
available experimental data. Estimates of the standard
Fig. 6. Overview of fitting procedure.
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fitting algorithm, but these estimates may not be accurate
especially if the noise level is high [39]. Therefore Monte
Carlo simulations (i.e., repeating the same fit several
hundred times with the same noise level, but a different
noise realization) are the tool of choice to evaluate the
robustness of the model.
An example of bunderdetermined Q problem occurs when
fitting the glutamate C4 time course with a one-compartment
model while keeping both VTCA and VX as free parameters
(Fig. 7). In that case, the glutamate C4 curve is perfectly
fitted, but Monte Carlo simulations show that the determi-
nation of VTCA and VX is not reliable, because VTCA and VX
values are spread over a large range of values.
When an underdetermined problem like this occurs, two
different solutions can be adopted.Fig. 7. Fit of glutamate C4 labeling curve with a one-compartment model. (A) Fi
simulation with two free parameters VTCA and VX showing that the fit is not ro
(C) Effect of constraining VX to either 50 or 1 Amol g1 min1. The fit is nearl
depending on the assumption on VX.The first option is to reduce the number of degrees of
freedom in the model by constraining some of the free
parameters. This can be done in the above example by fixing
VX to a specific value. However, the specific assumption on
VX can have a profound impact on the calculated VTCA. For
example, in a study by Henry et al. [38], it was shown that
fitting the glutamate C4 time course while assuming VX to
be very fast (VX=50 Amol g1 min1) resulted in a VTCA
value after fitting of 0.43 Amol g1 min1. When VX was
constrained to 1 Amol g1 min1, VTCA was found to be
0.66 Amol g1 min1, a more than 50% increase compared
to the value found with VX=50 Amol g1 min1.
There is still no consensus on the value of VX. Early
studies have suggested that VX was very fast compared to
VTCA [40]. Later studies have challenged this finding
[13,28,38,41] and have found that VX is comparable tot of glutamate C4 with two free parameters VTCA and VX. (B) Monte Carlo
bust when fitting the glutamate C4 curve alone with two free parameters.
y identical, but the resulting value of VTCA is changed by more than 50%
Fig. 8. Fit of both glutamate C4 and glutamate C3 labeling curves with a one-compartment model. (A) Best fit and (B) Monte Carlo simulation showing that the
fit is more robust when fitting both glutamate C4 and C3 curves than when fitting the glutamate C4 curve alone.
Fig. 9. Two-compartment model. Reproduced with permission from
Ref. [13].
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supported by measurements in isolated brain mitochondria
[43] and is consistent with the fact that VX may reflect
malate–aspartate shuttle activity. Unfortunately, precise
determination of VX in
13C modeling studies remains
hampered by the intrinsically low numerical accuracy on
the determination of this particular flux.
The second option when facing an underdetermined
problem is to increase the amount of experimental data in
the modeling. In the case of glutamate analysis with a
one-compartment model, this can be done by analyzing
not only the GluC4 time course, but also the GluC3
time course (Fig. 8). In that case, Monte Carlo simula-
tions clearly show that the modeling is more robust,
leading to values of both VTCA and VX that are well deter-
mined (Fig. 8B).
4.5. Evaluation of fit reliability: sensitivity analysis
In addition to Monte Carlo simulations, the sensitivity of
the modeling to the various assumptions needs to be
evaluated. This can be done by modifying assumptions
and determining the resulting effect on the fitted parameter
values. An example of sensitivity analysis described earlier
(Section 4.4) is the sensitivity of VTCA (up to 50%) to an
assumption on VX when fitting only the glutamate C4
turnover curve. Note that constraining VX when fitting both
GluC4 and GluC3 time courses will not affect VTCA as
much as when fitting GluC4 alone, but may introduce
nonrandom residuals.
When fitting multiple time courses, 13C time courses for
different carbon positions need to be correctly scaled
relative to each other. If the relative scaling is not correct
(for example due to a possible bias in the quantification of
NMR spectra), then the value of fitted parameters may be
affected. For example, when fitting both glutamate C4 and
glutamate C3, wrong scaling of the C3 curve relative to C4
will affect both VTCA and VX [38].4.6. Two-compartment model vs. one-compartment model
In this review, we have focused primarily on the one-
compartment model to measure VTCA. Since glutamate is
mostly neuronal, the VTCA value obtained with this model
reflects primarily neuronal VTCA. The principles and ideas
discussed in this review are directly applicable to more
complex models such as two-compartment models.
Most of the recent developments in the field of metabolic
modeling in the brain have used a two-compartment model
that takes into account the cellular compartmentation
between neurons and astrocytes (Fig. 9). In contrast to using
a one-compartment model, which allows only determination
of (mostly neuronal) VTCA and VX using glutamate labeling
time courses, using a two-compartment model potentially
allows for the measurement of many more metabolic fluxes,
including the glial TCA cycle rate (VTCA(G)), the pyruvate
carboxylase flux (VPC) and the glutamate–glutamine cycle
(termed VCYCLE or VNT), which may reflect directly
glutamatergic neurotransmission.
The development of two-compartment models was
initiated with the studies of Sibson et al. [8,44] showing
P.-G. Henry et al. / Magnetic Resonance Imaging 24 (2006) 527–539538that the glutamate–glutamine cycle flux was a quantita-
tively significant pathway for glutamine synthesis in the
brain. In these studies, the model was not fully two-
compartmental, in that it did not include free parameters
for the glial TCA cycle or the pyruvate carboxylase flux.
The model was refined in the next few years to include a
complete glial compartment with its own TCA cycle, and
with pyruvate carboxylase activity in the glial compart-
ment [13,29,45]. Some models currently in use consist of
up to seven free parameters: VTCA(N), VTCA(G), VX, VDIL,
VNT, VPC and an additional flux termed VEX for iso-
topic dilution of 13C label in glutamine through exchange
with unlabeled glutamine in the blood [14]. More free
parameters may even be added as models evolve. The
implementation of three-compartment models (glutamater-
gic neurons, GABAergic neurons and astrocytes) has also
been reported [46].
In spite of the complexity of two-compartment models,
no systematic evaluation of their robustness has been
reported so far, and more work is clearly needed in this
area. Since two-compartment models are more complex
than one-compartment models, it can be expected that
more experimental data are needed to achieve robust
modeling. For example, since differential labeling of C2
and C3 positions of glutamate and glutamine from
[1-13C]glucose is obtained through the pyruvate carboxylase
flux, information from C3 and C2 labeling time courses
may be expected to provide a more reliable determination
of VPC.5. Conclusion
13C metabolic modeling is still an evolving field.
Although this review has focused on the one-compartment
model to illustrate the key points in metabolic modeling,
much progress can be expected in the next few years as two-
compartment models are being refined and validated. We
expect Monte Carlo simulations to play a key role in the
assessment of the robustness of two-compartment models in
a variety of experimental conditions.
With the availability of very high magnetic fields for
human studies (7 and 9.4 T), decoupling will most likely
become a limiting factor, and new approaches are being
developed to perform 13Cmeasurements without decoupling,
using either indirect detection [47,48] or direct detection [49].
Progress in the quantitation of indirect 1H[13C] spectra is
also expected as the effect of strong coupling is being
investigated [36,37].
The potential of 13C metabolic modeling to noninvasively
measure glucose oxidative metabolism in neurons and glia
and glutamatergic neurotransmission provides a huge incen-
tive to make this approach more robust and more wide-
spread than it is now. It is our hope that this review will
encourage new investigators to begin working with this
fascinating tool.Acknowledgments
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